Cancel
Adicet Bio
See Linkedin
Adicet Bio Employees
7 people indexed:
-
0rpu36@r96vzpg44.386 Sign up to see email
-
48ks3g@4l792zgj3.303 Sign up to see email
-
q1lnxv@17qn98fn2.7j6 Sign up to see email
-
3rwpvv9@2z3r64g3u.nvk Sign up to see email
-
hy7rjuz@z9p5k24nv.v1p Sign up to see email
-
z7yp66@7v26qj0r7.7h8 Sign up to see email
-
8k2q31l@gxl0lq3l9.8gz Sign up to see email
Adicet Bio Company Information
Adicet Bio focuses on advancing a new generation of immune cell therapy using genetically engineered gamma delta T cells. These cells are modified with chimeric antigen receptors (CARs) to improve selective targeting of tumors, offering a promising approach to treat both hematological cancers and solid tumors. The company has developed a proprietary cell platform that enables the activation, engineering, and expansion of gamma delta T cells. Unlike alpha beta T cells, gamma delta T cells have shown superior potential in tumor eradication and operate in an MHC-independent manner, which significantly lowers the risk of Graft vs Host Disease. Adicet Bio has successfully established a robust process for activating and expanding various subsets of gamma delta T cells for clinical applications. The company has actively participated in significant industry events, including the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting and the 2024 Canaccord Genuity Horizons in Oncology Virtual Conference.
Report inaccurate information
Report inaccurate information
